Abraxane (Celgene) data for Pancreatic Cancer published in NEJM

Results of the MPACT Phase III clinical trial of Abraxane (paclitaxel protein-bound particles for injectable suspension), from Celgene, in combination with gemcitabine in patients with Pancreatic Cancer were published in the New England Journal of Medicine. Results demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months). It also demonstrated a statistically significant improvement in key secondary endpoints compared to gemcitabine alone, including a 31% reduction in the risk of progression or death with a median progression-free survival of 5.5 vs. 3.7 months.

These results led to the FDA�s approval of Abraxane in September 2013 for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. See: "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine," Von Hoff DD, Ervin T, Arena FP, et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1304369.